NCT04705883

Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors

Vaginal Prasterone In The Treatment Of Vaginal Atrophy In Patients With Breast Cancer Treatment With Aromatase Inhibitors (Vibra Study)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Hospital Clinic of Barcelona · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

VAGINAL PRASTERONE in the treatment of VAGINAL ATROPHY IN PATIENTS WITH BREAST CANCER TREATMENT WITH AROMATASE INHIBITORS (VIBRA STUDY)

Detailed description

Verify a clinical improvement of AVV without increasing levels of ultrasensitive blood estradiol in breast cancer survivors treated with aromatase inhibitors by administering vaginal prasterone.

Conditions

• Vulvar Atrophy
• Breast Cancer
• Genitourinary Syndrome of Menopause

Interventions

Type	Name	Description
DRUG	Prasterone (DHEA), Micronized	Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.

Timeline

• Start date: 2020-09-01
• Primary completion: 2021-11-08
• Completion: 2021-12-01
• First posted: 2021-01-12
• Last updated: 2022-02-22

Locations

1 site across 1 country: Spain